Nobuhiko Hiraga
Overview
Explore the profile of Nobuhiko Hiraga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duehren S, Uchida T, Tsuge M, Hiraga N, Uprichard S, Etzion O, et al.
Virus Res
. 2024 Aug;
349:199451.
PMID: 39168375
Recent studies indicate that treatment of chronic hepatitis D virus (HDV) with either pegylated interferon (IFN)λ or pegylated IFNα monotherapy leads to a dramatic decline in HDV RNA. Herein, we...
2.
Hailegiorgis A, Ishida Y, Collier N, Imamura M, Shi Z, Reinharz V, et al.
PLoS Comput Biol
. 2023 Aug;
19(8):e1011309.
PMID: 37535676
Hepatitis B virus (HBV) infection kinetics in immunodeficient mice reconstituted with humanized livers from inoculation to steady state is highly dynamic despite the absence of an adaptive immune response. To...
3.
Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha G, et al.
J Gastroenterol
. 2019 Feb;
54(7):650-659.
PMID: 30790056
Background And Aims: The clinical course and responsiveness to antiviral treatments differs among hepatitis B virus (HBV) genotypes. However, the cause of these differences is unclear. In the present study,...
4.
Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, et al.
Virology
. 2018 Sep;
525:48-61.
PMID: 30240958
The events in the immune response to hepatitis B virus (HBV) remain unclear. We analyzed the direct influence of HBV on gene expression in human hepatocytes under immunodeficient conditions using...
5.
Nomura M, Tsuge M, Uchida T, Hiraga N, Kurihara M, Tsushima K, et al.
J Viral Hepat
. 2018 Jul;
25(12):1555-1564.
PMID: 29998562
The activation of hepatitis B virus (HBV)-related hepatitis is associated with both natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). We analyzed the association between the immune response and...
6.
Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, et al.
J Gen Virol
. 2018 Jun;
99(8):1058-1065.
PMID: 29916799
Combined daclatasvir (DCV)/asunaprevir (ASV) plus beclabuvir (BCV) treatment shows a high virological response for genotype 1b chronic hepatitis C patients. However, its efficacy for patients for whom previous direct-acting antiviral...
7.
Ishida Y, Chung T, Imamura M, Hiraga N, Sen S, Yokomichi H, et al.
Hepatology
. 2018 Mar;
68(2):473-484.
PMID: 29572897
Conclusion: HBV infection in uPA/SCID chimeric mice is highly dynamic despite the absence of an adaptive immune response. Serum HBV t in humanized uPA/SCID mice was estimated to be ∼1...
8.
Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, et al.
J Gastroenterol
. 2017 Jul;
53(2):269-280.
PMID: 28741270
Background And Aims: The risk factors in the progression of nonalcoholic fatty liver disease (NAFLD) have not been fully clarified. Porphyromonas gingivalis (P.g) has been considered to be a confounding...
9.
Uchida T, Imamura M, Hayes C, Hiraga N, Kan H, Tsuge M, et al.
Antimicrob Agents Chemother
. 2017 Jul;
61(9).
PMID: 28696237
Nucleot(s)ide analogues and peginterferon (PEG-IFN) treatment are the only approved therapies for chronic hepatitis B virus (HBV) infection. However, complete eradication of the virus, as indicated by persistent loss of...
10.
Tsuge M, Uchida T, Hiraga N, Kan H, Makokha G, Abe-Chayama H, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(6).
PMID: 28373196
Although nucleot(s)ide analogues and pegylated interferon alpha 2a (PEG-IFN-α2a) can suppress hepatitis B virus (HBV) replication, it is difficult to achieve complete HBV elimination from hepatocytes. A novel site-specific pegylated...